AKRO vs. ALBO, ENTA, CBAY, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Albireo Pharma (ALBO), Enanta Pharmaceuticals (ENTA), CymaBay Therapeutics (CBAY), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Albireo Pharma (NASDAQ:ALBO) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
Albireo Pharma received 199 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 61.49% of users gave Akero Therapeutics an outperform vote while only 56.65% of users gave Albireo Pharma an outperform vote.
Albireo Pharma has higher revenue and earnings than Akero Therapeutics. Albireo Pharma is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.
94.3% of Albireo Pharma shares are held by institutional investors. 6.9% of Albireo Pharma shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Akero Therapeutics has a net margin of 0.00% compared to Akero Therapeutics' net margin of -228.51%. Albireo Pharma's return on equity of -27.72% beat Akero Therapeutics' return on equity.
Albireo Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500.
Akero Therapeutics has a consensus price target of $41.13, indicating a potential upside of 118.52%. Given Albireo Pharma's higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Albireo Pharma.
In the previous week, Akero Therapeutics had 11 more articles in the media than Albireo Pharma. MarketBeat recorded 11 mentions for Akero Therapeutics and 0 mentions for Albireo Pharma. Albireo Pharma's average media sentiment score of 0.48 beat Akero Therapeutics' score of 0.20 indicating that Akero Therapeutics is being referred to more favorably in the news media.
Summary
Akero Therapeutics beats Albireo Pharma on 11 of the 16 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akero Therapeutics Competitors List
Related Companies and Tools
